Intra-abdominal infections: Etiology, epidemiology, microbiological diagnosis and antibiotic resistance issues;Eziologia, epidemiologia e diagnostica microbiologica delle infezioni intraddominali

Infezioni in Medicina

Volumn 16, Issue SUPPL. 1, 2008, Pages 8-18

  Nicoletti, Giuseppe ^a   Nicolosi, Daria ^a   Rossolini, Gian Maria ^b   Stefani, Stefania ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Intra abdominal infections; Polimicrobial infections; Resistances

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; CEFEPIME; CEFOTAXIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; LINEZOLID; OXACILLIN; VANCOMYCIN;

ABDOMINAL INFECTION; ABDOMINAL SURGERY; ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; CANDIDA; ENTEROCOCCUS; FOREIGN BODY; HOSPITAL INFECTION; HUMAN; MICROBIOLOGICAL EXAMINATION; MULTIDRUG RESISTANCE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PSEUDOMONAS AERUGINOSA; REVIEW; RISK FACTOR; STAPHYLOCOCCUS AUREUS;

ABDOMINAL ABSCESS; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GASTROINTESTINAL DISEASES; HUMANS; MICROBIAL SENSITIVITY TESTS; PERITONITIS; SICILY; SURGICAL WOUND INFECTION;

EID: 42049093178     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Stijn B., De Waele JJ. Critical Issues in the clinical management of complicated intra-abdominal infections. Drugs. 65, 1611-1620, 2005.
2. Swenson RM., Lorber B., Michaelson TC., et al. The bacteriology of intraabdominal infections. Arch. Surg. 109 (3), 398-9, 1974.
3. Onderdonk AB., Bartlett JG., Louie T. Microbial synergy in experimental intra-abdominal abscess. Infect. Immun. 13, 22-26, 1976.
4. Montravers P., Mohler J., Saint Julien L., Carbon C. Evidence of the proinflammatory role of Enterococcus faecalis in polymicrobial peritonitis in rats. Inf. Immun. 65, 144-149, 1997.
5. Van der Waaij D. Colonization resistance of the digestive tract: clinical consequences and implications. J. Antimicrob Chemother. 10, 263-270, 1982.
6. Laterre PF., Colardyn F., Delmee M., de Waele J. Legrand CL., Van Eldere J., et al Antimicrobial therapy for intra-abdomianl infections: guidelines from the infectious diseases advisory board. Acta. Chir. Belga. 106, 2-21, 2006.
7. Nicoletti G. Schito G., Fadda G., Boros S., Nicolosi D., Marchese A., et al. Bacterial isolates from severe infections and their antibiotic susceptibility patterns in Italy: a nationwide study in the hospital settings. J. Chemother. 18 (8), 24-37, 2006.
8. Solomkin JS., Yellin AE., Rotsein OD., Nicolas V., Dellinger EP., Tellado JM., et al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intra-abdominal infections. Ann. Surg. 237, 235-245, 2003.
9. Seguin P., Laviolle B., Chavanaz C., Donnio PY., Gautier-Leferisf AL., Campion JP., and Malledant Y. Factors associated with mutlidrug-resistant bacteria in secondary peritonitis: impact on antibiotic therapy. Clin. Microbiol. Inf. 12, 980-985, 2006.
10. Borbone S., Cascone C., Santagati M., Mezzatesta ML., Stefani S. The bactericidal activity of ertapenem against major intra-abdominal pathogens. Int. J. Antimicrob. Agents. 28, 396-401, 2006.
11. Turner PJ., Greenhalgh JM., Edwards JR., McKellar J. The MYSTIC (meropenem yearly susceptibility test information collection) programme. Intern. J. Antimicrob. Agents. 13, 117-125, 1999.
12. Pfaller MA Jones RN. MYSTIC (meropenem yearly susceptibility test information collection) results from the Americas: resistance implications in the treatment of serious infections. J. Antimicrob. Chemother. 46, 25-37, 2000.
13. Rossi F., Baquero F., Hsueh PR., Paterson DL., Bochicchio GV., Snyder TA., et al. In vitro susceptibilities of aerobic and anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J. Antimicrob. Chemother. 58, 205-210, 2006.
14. Spanu T., Luzzaro F., Perilli M. Amicosante G., Toniolo A., Fadda G. and The Italian ESBL Study Group. Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to β-lactams and other antimicrobial drugs. Antimicrob. Agents Chemother. 46, 196-202, 2002.
15. Luzzaro F., Mezzatesta ML., Mugnaioli C., Perilli MG., Stefani S., Amicosante G., et al. Trends in production of extended-spectrum beta-lactamases among Enterobacteria of medical interest: report of the second Italian Nationwide Survey. J. Clin. Microbiol. 44, 1659-1664, 2006.
16. Montravers P.,Gauzit R., Müller C., Marmuse JP., Fichelle A., Desmonts JM. Emergence and antibiotic resistant bacteria in case of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial chemotherapy. Clin. Inf. Dis. 23, 486-494, 1996.
17. Stefani S. Emergence of multi-drug resistant Gram-positive bacteria and new active antibiotics. Curr. Med Chem. Anti-Infective Agents. 4, 235-257, 2005.
18. Stefani S., Varaldo PE. Epidemiology of MRS in Europe. Clinical Microbiol. and Infection. 9 (12), 1179-1186, 2003.
19. Mato R., Campanile F., Stefani S., Crisostomo ML, Santagati M., Santos Sanchez I., de Lencastre H. Clonal types and multidrug resistance patterns of methicillin-resistant Staphylococcus aureus (MRSA) recovered in Italy during the 1990s. Microbial. Drug. Resistance 10, 106-113, 2004.
20. Grundmann H., Aires de Sousa M., Boyce J., Tiemersma E. Emergence and resurgence of methicillin-resistant Staphylococcus aureus as a public-health treat. Lancet 368, 874-885, 2006.
21. th ed. ASM Press, Washington, D.C. 41-67, 2003.
22. Robicsek A., Jacoby GA., Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect. Dis. 6, 629-640, 2006.
23. Perichon B., Courvalin P., Galimand M. Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. Antimicrob. Agents Chemother. 51, 2007, Epub ahead of print.
24. Robicsek A., Strahilevitz J., Sahm DF., Jacoby GA., Hooper DC. QNR prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States. Antimicrob. Agents Chemother. 50, 2872-2874, 2006.
25. Park CH., Robicsek A., Jacoby GA., Sahm D., Hooper DC. Prevalence in the United States of aac(6′)-Ib-cr encoding a ciprofloxacin-modifying enzyme. Antimicrob. Agents Chemother. 50, 3953-3955, 2006.
26. Paterson DL., Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin. Microbiol. Rev. 18 (8), 57-86, 2005.
27. Elliott E., Brink AJ., van Greune J., Els Z., Woodford N., Turton J., Warner M., Livermore DM. In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum β-lactamase. Clin. Infect. Dis. 42, 95-98, 2006.
28. Livermore DM., Woodford N. The β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol. 14, 13-20, 2006.
29. Waites KB., Duffy LB., Dowzicky MJ. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob. Agents Chemother. 50, 3479-3484, 2006.
30. Morosini MI., Garcia-Castillo M., Coque TM., Valverde A., Novais A., Loza E., Baquero F., Canton R. Antibiotic co-resistance in extended-spectrum-beta- lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob. Agents Chemother. 50, 2695-2699, 2006.
31. Souli M., Kontopidou FV., Koratzanis E., Antoniadou A., Giannitsioti E., Evangelopoulou P., Kannavaki S., Giamarellou H. In vitro activity of tigecycline against multiple-drug-resistant, including panresistant, gram-negative and gram-positive clinical isolates from Greek hospitals. Antimicrob. Agents Chemother. 50, 3166-3169, 2006.
32. Rossolini GM., Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin. Microbiol. Infect. 11 S4, 17-32, 2005.
33. Lepper PM., Grusa E., Reichl H., Hogel J., Trautmann M. Consumption of imipenem correlates with β-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 46, 2920-2925, 2002.
34. Bonomo RA., Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin. Infect. Dis. 43, S49-56, 2006.